Marksans Pharma's UK arm gets marketing approval for Sennosides 7.5 mg tablets
Shares of Marksans Pharma could remain in focus after the company announced that its wholly owned UK subsidiary, Relonchem Limited, has received marketing authorization for Sennosides 7.5 mg tablets from the UK Medicines & Healthcare Products Regulatory Agency (MHRA).
This regulatory clearance marks a significant step in the company's product expansion in the UK pharmaceutical market. Sennosides are typically used as a laxative in various therapeutic segments, and the approval strengthens Marksans' position in the gastrointestinal treatment category.
Marksans Pharma, headquartered in Mumbai, engages in the research, manufacturing, and marketing of generic pharmaceutical formulations across global markets. Its manufacturing facilities in India, the USA, and the UK are approved by top regulatory bodies, including USFDA, UKMHRA, and Australian TGA.
The company's product portfolio spans major therapeutic areas such as cardiovascular, central nervous system, anti-diabetic, pain management, gastroenterological, and anti-allergies.
Disclaimer: The information provided is for informational purposes only and should not be considered financial or investment advice. Stock market investments are subject to market risks. Always conduct your own research or consult a financial advisor before making investment decisions. Author or Business Upturn is not liable for any losses arising from the use of this information.
Aditya Bhagchandani serves as the Senior Editor and Writer at Business Upturn, where he leads coverage across the Business, Finance, Corporate, and Stock Market segments. With a keen eye for detail and a commitment to journalistic integrity, he not only contributes insightful articles but also oversees editorial direction for the reporting team.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Upturn
16 hours ago
- Business Upturn
INDIA bloc names ex-Supreme Court judge B. Sudarshan Reddy as Vice-Presidential candidate
By Aditya Bhagchandani Published on August 19, 2025, 13:06 IST Leaders of the INDIA bloc on Tuesday announced former Supreme Court judge B. Sudarshan Reddy as their candidate for the Vice-Presidential election scheduled for September 9. The announcement came after a huddle at Congress chief Mallikarjun Kharge's residence, where opposition leaders deliberated on fielding a common nominee. The move pits the Opposition against the BJP-led NDA, which on Sunday named Maharashtra Governor C.P. Radhakrishnan as its candidate. Radhakrishnan, a veteran of the Rashtriya Swayamsevak Sangh (RSS) and former president of the BJP's Tamil Nadu unit, is expected to be backed unanimously by the ruling alliance. Defence Minister Rajnath Singh had earlier reached out to opposition leaders, including Kharge, in an attempt to build support for a consensus choice, though the INDIA bloc ultimately decided to field its own nominee. The election was necessitated after Vice President Jagdeep Dhankhar resigned last month citing health reasons. The last date for filing nominations is August 21. The contest is expected to be closely watched, though the NDA holds a numerical advantage in the electoral college. In the last Vice-Presidential election, the Opposition fielded Margaret Alva, who lost to Dhankhar. The majority mark stands at 394 in the combined strength of both Houses of Parliament, which totals 786 members. Justice Reddy, who also served as the first Lokayukta of Goa, is being projected as a consensus and non-political choice, reflecting the Opposition's strategy to nominate a respected figure from outside active politics. Ahmedabad Plane Crash Aditya Bhagchandani serves as the Senior Editor and Writer at Business Upturn, where he leads coverage across the Business, Finance, Corporate, and Stock Market segments. With a keen eye for detail and a commitment to journalistic integrity, he not only contributes insightful articles but also oversees editorial direction for the reporting team.
Business Upturn
17 hours ago
- Business Upturn
Alembic Pharma gains as USFDA approves Macitentan tablets for pulmonary arterial hypertension
By Aditya Bhagchandani Published on August 19, 2025, 11:18 IST Shares of Alembic Pharmaceuticals Ltd were in focus on Tuesday, August 19, after the company announced that it has received final approval from the US Food & Drug Administration (USFDA) for its Macitentan Tablets, 10 mg. The product is a generic version of Actelion Pharmaceuticals' Opsumit tablets and is indicated for the treatment of pulmonary arterial hypertension (PAH) in adults to reduce the risk of disease progression and hospitalization. According to IQVIA data, the drug has an estimated market size of $1.18 billion for the 12 months ending June 2025. With this nod, Alembic's cumulative USFDA approvals now stand at 224 Abbreviated New Drug Applications (ANDAs), including 203 final approvals and 21 tentative approvals. The approval adds to the company's growing US generics portfolio, which has been a key driver of international business. Founded in 1907, Alembic is a vertically integrated pharmaceutical company with a strong presence in branded generics in India and a well-established footprint in the global generics market. The company manufactures and markets products across multiple therapeutic segments through its R&D-driven operations. Disclaimer: This article is for informational purposes only and should not be construed as investment advice. Ahmedabad Plane Crash Aditya Bhagchandani serves as the Senior Editor and Writer at Business Upturn, where he leads coverage across the Business, Finance, Corporate, and Stock Market segments. With a keen eye for detail and a commitment to journalistic integrity, he not only contributes insightful articles but also oversees editorial direction for the reporting team.
Business Upturn
17 hours ago
- Business Upturn
Kernex Microsystems shares rise over 2% after bagging Rs 151 crore KAVACH order from West Central Railway
By Aditya Bhagchandani Published on August 19, 2025, 10:44 IST Shares of Kernex Microsystems (India) Ltd gained over 2% in Monday's trade after the company announced a fresh order win for the Indian Railways' indigenous KAVACH Automatic Train Protection (ATP) system. At 10:43 am, the stock was trading at ₹1,076 apiece on the NSE, up 2.31% (₹24.30) from the previous close of ₹1,051.70. During the session, the stock touched a high of ₹1,079.70 and a low of ₹999.20. Kernex currently commands a market capitalisation of ₹18.10 billion and has delivered sharp gains from its 52-week low of ₹621.55, though still off its high of ₹1,580. The company, through its Kernex–KEC Consortium, secured an order worth ₹151.41 crore (including GST) from West Central Railway, Bhopal Division. The scope of work involves deployment of the KAVACH ATP system on the UHF backbone along with optical fibre cable (OFC) and route diversity. The project will be completed in 600 days across sections including Itarsi–Khandwa and Bina–Ruthiyai . With this contract, Kernex's cumulative KAVACH order book since April 2024 has risen to ₹3,136.53 crore, underscoring strong momentum in the rail safety modernisation drive. Kernex, a niche player in railway safety and signalling solutions, continues to benefit from the government's aggressive push towards rail safety. Analysts say the company's expanding execution pipeline could further support stock performance, though valuations remain on the higher side with a P/E ratio of 36.03. Disclaimer: This article is for informational purposes only and should not be construed as investment advice. Ahmedabad Plane Crash Aditya Bhagchandani serves as the Senior Editor and Writer at Business Upturn, where he leads coverage across the Business, Finance, Corporate, and Stock Market segments. With a keen eye for detail and a commitment to journalistic integrity, he not only contributes insightful articles but also oversees editorial direction for the reporting team.
